Featured Courses

The pathobiology of myelofibrosis continues to advance and the current understanding of myelofibrosis is complex. Guidelines and recommendations for the diagnosis of myelofibrosis, including the revised WHO criteria for myelofibrosis, is controversial. The clinical trial data on JAK2 inhibitor therapeutics has changed the clinical approach to...
Emerging Developments in Hepatitis C Virus Treatment
1.00
  • AMA PRA Category 1 Credit(s)™
The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2013 was very dynamic during this exciting era of newer pharmacotherapies to manage patients with hepatitis C. Nancy Reau, MD has reviewed and selected the major clinical trial data presented at AASLD 2013 to develop this comprehensive...
Advances in the Management of Patients with Obesity
1.00
  • AMA PRA Category 1 Credit(s)™
ObesityWeek 2013 was held on November 11–16, in Atlanta, GA and presented important data for the successful management of patients with obesity. At present, healthcare practitioners have a more focused understanding of obesity as a multi-faceted illness that includes newer concepts such as healthy obese and non-healthy obese. The...
The 29th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) was presented in Copenhagen, Denmark on October 2–5, 2013. As expected, neurologists around the globe experienced current concepts, science, and clinical trial data for multiple sclerosis and Multiple Sclerosis (MS)-related diseases....
Advances in the Management of Patients with Hyponatremia
2.00
  • AMA PRA Category 1 Credit(s)™
This continuing medical education activity represents a comprehensive summary of the diagnosis and treatment of all types of hyponatremia. The expert faculty present specific treatment recommendations according to the extracellular fluid volume status and the specific etiology of the hyponatremia. Rationale for effective treatment strategies are...
During this interactive enduring CME activity, (Emergency Department) specialists will discuss common challenges of managing patients with community-acquired bacterial pneumonia (CABP), including the integration of newer agents into the standard anti-infective mix. Decisions made at this pivotal point of care can affect both patient outcomes and...
Breakthrough pain (BTP) occurs in many cancer patients. Often, short-acting opioids do not have the pharmacokinetic profile to match the rapid and unpredictable onset of BTP. With their rapid onset of action, transmucosal immediate-release fentanyl (TIRF) formulations offer distinct advantages in the treatment of BTP; however, the availability of...
Patients with advancing metastatic breast cancer present the most challenging management decisions for the practicing oncologist. Over recent years, newer data on microtubule dynamics inhibitor therapeutics have shown improved overall survival for patients previously treated with traditional first and second line chemotherapies. This CME program...
At present, the field of multiple sclerosis (MS) research has made remarkable progress revealing innovative agents, both currently approved for treatment and emerging therapies. With the availability of three oral agents, clinical decision-making and therapeutic strategies are increasingly important. This unique webcast includes a panel of expert...
As with all premier textbooks, the time from actual publication to the release of a new edition creates a gap in the publication of information concerning recent changes in standard clinical practice. In the case of multiple sclerosis, which is rapidly changing and evolving, this is even more apparent. Given the varied expertise and clinical...